Teva-Sulindac · DIN 00745588 · 150 mg · tablet
General benefitMarketed · checked November 19, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Teva-Sulindac · DIN 00745588
Manufacturer: Teva Canada Limited; listing date 1996-10-01
Health Canada: Marketed since 2011-06-18 · brand TEVA-SULINDAC · ATC M01AB02 SULINDAC · form Tablet · route Oral · ingredients SULINDAC 150 MG · company Npr laboratories inc. · schedule Prescription
Teva-Sulindac: Formulary list price $0.44 per unit (the source does not state the unit; exact figure $0.4427). What the ministry pays, not the patient.
Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 00745588)
Source record
DIN 00745588: Teva-Sulindac
Raw flags: sec3=Y
Item: 280804042; group id 394; item number 0943; lccId None; manufacturer id TEV
Source form: Tab; strength: 150mg
Recorded listing: General benefit
Source prices (unrounded): $0.4427; ministry $0.4427
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=00745588
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=9238
Therapeutic Notes (formulary)
NSAIDs have a high rate of serious adverse effects in the elderly. When prescribing NSAIDs, the minimal effective dose for the shortest period of time should be used. In nonspecific pain and/or osteoarthritis, in the absence of joint inflammation (swelling), acetaminophen is a better first choice for analgesia. The most effective treatment to prevent NSAID-gastritis is misoprostol; although H-2 antagonists, such as ranitidine or cimetidine, are commonly used, they are not as effective. NSAIDs can significantly aggravate hypertension and congestive heart failure; ASA in doses below 1 gram per day is a better choice than other NSAID options if anti-inflammatory effects are required in patients with these conditions. Low dose ASA has additional benefits for anti-platelet indications that are not provided by other NSAIDs, and should be given in preference or in addition to other NSAIDs for patients with vascular indications.
Interchangeable products
Clinoril · DIN 00456888 · not recorded
Shortage status: not checked (no credentials)